

Results of Annual General Meeting

Valencia, CA, USA, Australia and United Kingdom, — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the results of the Annual General Meeting.

A poll was called for each of the resolutions, please refer to page 3 for the proxy analysis and comparison to poll outcome. The Annual General Meeting of the Members of Avita Medical Limited was held at K & L Gates, Level 25, 525 Collins Street, Melbourne Victoria on 30 November 2017 at 11:00 AM, with the poll on the resolutions set out below:

1 ADOPTION OF REMUNERATION REPORT

	Number	%
Votes cast 'FOR' the motion	235,353,519	79.95
Votes cast 'AGAINST' the motion	59,039,191	20.05
TOTAL VOTES CAST	294,392,710	100.00
Votes "Abstained"	1,990,147	

The resolution was carried as an ordinary resolution.

2 RE-ELECTION OF DIRECTOR - JEREMY CURNOCK COOK

	Number	%
Votes cast 'FOR' the motion	308,757,993	92.42
Votes cast 'AGAINST' the motion	25,325,214	7.58
TOTAL VOTES CAST	334,083,207	100.00
Votes "Abstained"	2,471,975	

The resolution was carried as an ordinary resolution.

3 RATIFICATION OF PRIOR ISSUE - SHARES

	Number	%
Votes cast 'FOR' the motion	150,141,855	92.10
Votes cast 'AGAINST' the motion	12,886,245	7.90
TOTAL VOTES CAST	163,028,100	100.00
Votes "Abstained"	727,426	

The resolution was carried as an ordinary resolution.

4

APPROVAL OF 10% PLACEMENT CAPACITY

	Number	%
Votes cast 'FOR' the motion	306,837,319	91.55
Votes cast 'AGAINST' the motion	28,303,742	8.45
TOTAL VOTES CAST	335,141,061	100.00
Votes "Abstained"	1,414,121	

The resolution was carried as a special resolution.

5

**APPROVAL OF THE ISSUE OF LONG TERM INCENTIVE
RIGHTS TO DR MICHAEL PERRY**

	Number	%
Votes cast 'FOR' the motion	296,211,657	88.30
Votes cast 'AGAINST' the motion	39,242,905	11.70
TOTAL VOTES CAST	335,454,562	100.00
Votes "Abstained"	1,038,966	

The resolution was carried as an ordinary resolution.

Thursday, 30 November 2017
Voting Results

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth).

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 ADOPTION OF REMUNERATION REPORT	Ordinary	199,721,339 76.91%	58,239,191 22.43%	1,713,980 0.66%	1,990,147	235,353,519 79.95%	59,039,191 20.05%	1,990,147	Carried
2 RE-ELECTION OF DIRECTOR - JEREMY CURNOCK COOK	Ordinary	273,013,120 91.23%	24,525,214 8.20%	1,688,286 0.57%	2,471,975	308,757,993 92.42%	25,325,214 7.58%	2,471,975	Carried
3 RATIFICATION OF PRIOR ISSUE - SHARES	Ordinary	113,634,738 88.66%	12,886,245 10.05%	1,650,530 1.29%	727,426	150,141,855 92.10%	12,886,245 7.90%	727,426	Carried
4 APPROVAL OF 10% PLACEMENT CAPACITY	Special	271,128,353 90.29%	27,503,742 9.16%	1,652,379 0.55%	1,414,121	306,837,319 91.55%	28,303,742 8.45%	1,414,121	Carried
5 APPROVAL OF THE ISSUE OF LONG TERM INCENTIVE RIGHTS TO DR MICHAEL PERRY	Ordinary	260,566,194 86.66%	38,442,905 12.79%	1,650,530 0.55%	1,038,966	296,211,657 88.30%	39,242,905 11.70%	1,038,966	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

ABOUT AVITA MEDICAL LIMITED

Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. Our medical devices work by preparing a Regenerative Epithelial Suspension (RES™), an autologous suspension comprised of the patients' own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This is then applied to the area to be treated.

In all countries outside of Europe, our portfolio is marketed under the ReCell® brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics.

ReCell® is TGA-registered in Australia, and CFDA-cleared in China. In the United States, while a PMA for ReCell® is currently under review by the FDA, the product continues to be an investigational device limited by federal law to investigational use.

In Europe, our portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names. ReCell® is designed for the treatment of burns and plastic reconstructive procedures; ReGenerCell™ has been formulated for chronic wounds including leg and foot ulcers; and ReNovaCell™ is tailored for aesthetic applications including the restoration of pigmentation. To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "intend," "could," "may," "will," "believe," "estimate," "look forward," "forecast," "goal," "target," "project," "continue," "outlook," "guidance," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company's control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

Australia Monsoon Communications Sarah Kemter Phone: +61 (0)3 9620 3333 Mobile: +61 (0)407 162 530 sarahk@monsoon.com.au	USA Westwicke Partners Caroline Corner Phone +1 (415) 202-5678 caroline.corner@westwicke.com Avita Medical Ltd
--	---

	<p>Tim Rooney Chief Financial Officer Phone +1 (661) 367-9161 trooney@avitamedical.com</p>
--	--